# US 2003/0069252 A1 · Piperazine derivatives useful as CCR5 antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0069252 A1
- Document ID: US20030069252A1
- Status: Published application
- Kind: A1
- Application number: 10/061,011
- Filed: 2002-01-30
- Published: 2003-04-10
- Earliest claimed: 1999-05-04
- Assignees: Schering Corporation
- Inventors: Bahige M. Baroudy; John W. Clader; Hubert B. Josien; Stuart W. McCombie; Brian A. McKittrick; Michael W. Miller; Bernard R. Neustadt; Anandan Palani; Elizabeth M. Smith; Ruo Steensma; Jayaram R. Tagat; Susan F. Vice; Mark A. Laughlin; Eric Gilbert; Marc A. Labroli
- Web page: https://patentgrep.com/patent/US20030069252A1

## CPC

- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- C07D 211/58: attached in position 4
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 409/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The use of CCR5 antagonists of the formula 1 or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.

## Claims

### Claim 1

A compound represented by the structural formula II
428
or a pharmaceutically acceptable salt thereof, wherein
(1) Ra is R8a-phenyl, R8b-pyridyl, R8b-thiophenyl or R8-naphthyl;
R1 is hydrogen or C1-C6 alkyl;
R2 is R9, R10, R11-phenyl; R9, R10, R11-substituted 6-membered heteroaryl; R9, R10, R11-substituted 6-membered heteroaryl N-oxide; R12, R13-substituted 5-membered heteroaryl; naphthyl; fluorenyl; diphenylmethyl,
429
R3 is hydrogen, C1-C6 alkyl, (C1-C6)alkoxy(C0-C6)alkyl, C3-C10 cycloalkyl, C3-C10 cycloalkyl(C1-C6)alkyl, R8-phenyl, R8-phenyl(C1-C6)alkyl, R8-naphthyl, R3-naphthyl(C1-C6)alkyl, R8-heteroaryl or R8-heteroaryl(C1-C6)alkyl;
R4, R5, R7 and R13 are independently selected from the group consisting of hydrogen and (C1-C6)-alkyl;
R6 is hydrogen, C1-C6 alkyl or C2-C6 alkenyl;
R8 is 1 to 3 substituents independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, —CF3, CF3O—, CH3C(O)—, —CN, CH3SO2—, CF3SO2—, R14-phenyl, R14-benzyl, CH3C(═NOCH3), CH3C(═NOCH2CH3),
430
—NH2, —NHCOCF3, —NHCONH(C1-C6 alkyl), —NHCO(C1-C6 alkyl), —NHSO2(C1-C6 alkyl), 5-membered heteroaryl and
431
wherein X is —O—, —NH— or —N(CH3)—;
R8a is 1 to 3 substituents independently selected from the group consisting of hydrogen, halogen, —CF3, CF3O—, —CN, CF3SO2—, R14-phenyl, —NHCOCF3, 5-membered heteroaryl and
432
wherein X is as defined above;
R8b is 1 to 3 substituents independently selected from the group consisting of hydrogen, halogen, —CF3, CF3O—, CH3C(O)—, —CN, CF3SO2—, R14-benzyl, CH3C(═NOCH3), CH3C(═NOCH2CH3),
433
—NHCOCF3, 5-membered heteroaryl and
434
wherein X is as defined above;
R9 and R10 are independently selected from the group consisting of (C1-C6)alkyl, halogen, —NR17R18, —OH, —CF3, —OCH3, —O-acyl, —OCF3 and —Si(CH3)3;
R11 is R9, hydrogen, phenyl, —NO2, —CN, —CH2F, —CHF2, —CHO, —CH═NOR17, pyridyl, pyridyl N-oxide, pyrimidinyl, pyrazinyl, —N(R17)CONR18R19, —NHCONH(chloro-(C1-C6)alkyl), —NHCONH((C3-C1)cycloalkyl(C1-C6)alkyl), —NHCO(C1-C6)alkyl, —NHCOCF3, —NHSO2N((C1-C6)alkyl)2, —NHSO2(C1-C6)alkyl, —N(SO2CF3)2, —NHCO2(C1-C6)alkyl, C3-C10 cycloalkyl —SR, —SOR2, —SO2R20, —SO2NH(C1-C6 alkyl), —OSO2(C1-C6)alkyl, —OSO2CF3, hydroxy(C1-C6)alkyl, —CONR17R18, —CON(CH2CH2—O—CH3)2, —OCONH(C1-C6)alkyl, —CO2R17, —Si(CH3)3 or —B(OC(CH3)2)2;
R12 is (C1-C6)alkyl, —NH2 or R14-phenyl;
R14 is 1 to 3 substituents independently selected from the group consisting of hydrogen, (C1-C6) alkyl, —CF3, —CO2R17, —CN, (C1-C6)alkoxy and halogen;
R15 and R16 are independently selected from the group consisting of hydrogen and C1-C6 alkyl, or R15 and R16 together are a C2-C5 alkylene group and with the carbon to which they are attached form a spiro ring of 3 to 6 carbon atoms;
R17, R18 and R19 are independently selected from the group consisting of H and C1-C6 alkyl; and
R20 is C1-C6 alkyl or phenyl; or
(2) Ra is R8-phenyl, R8-pyridyl or R8-thiophenyl; R2 is fluorenyl, diphenylmethyl,
435
and R1, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19 and R20 are as defined in (1).

### Claim 2 (depends on 1)

A compound of claim 1 wherein Ra is R8a-phenyl or R8-naphthyl.

### Claim 3 (depends on 2)

A compound of claim 2 wherein Ra is
436
wherein R8a is —CF3, CF3O— or halogen; or Ra is
437
wherein R8 is C1-C6 alkoxy.

### Claim 4 (depends on 1)

A compound of claim 1 wherein R3 is hydrogen, (C1-C6) alkyl, R8-phenyl, R8-benzyl or R8-pyridyl.

### Claim 5 (depends on 1)

A compound of claim 1 wherein R1 is hydrogen; R6 is hydrogen or methyl; R4 is methyl; and R5 and R7 are each hydrogen.

### Claim 6 (depends on 1)

A compound of claim 1 wherein R2 is R9, R10, R11-phenyl; R9, R10, R11-pyridyl or an N-oxide thereof; or R9, R10, R1-pyrimidyl.

### Claim 7 (depends on 6)

A compound of claim 6 wherein R2 is selected from the group consisting of
438
wherein R9 and R10 are selected from the group consisting of (C1-C6)alkyl, halogen, —OH and —NH2.

### Claim 8

A compound selected from the group consisting of those represented by the structural formula
31 439 wherein R, R3, R6 and R2 are as defined in the following table: R R3 R6 R2 440 441 H 442 443 444 —CH3 445 446 447 H 448 449 450 H 451 452 453 H 454 455 456 H 457 458 459 —CH3 460 461 462 —CH3 463 464 465 —CH3 466 467 468 —CH3 469 470 471 —CH3 472 473 474 —CH3 475 476 477 H 478 479 480 H 481 482 483 —CH3 484 485 486 —CH3 487 488 489 —CH3 490 491 492 —CH3 493 494 495 —CH3 496 497 H —CH3 498 499 H —CH3 500 501 H —CH3 502 503 H —CH3 504 505 506 —CH3 507 508 H H 509 510 511 H 512 513 514 —CH3 515 516 517 H 518 519 520 —CH3 521 522 523 H 524 525 526 H 527 528 529 H 530 531 532 H 533 534 535 —CH3 536 537 H —CH3 538 539 H —CH3 540 541 542 —CH2CH3 543 544 545 —CH2CH3 546 547 548 —CH2CH3 549 550 551 —CH3 552 553 554 —CH3 555 556 557 —CH3 558 559 560 —CH3 561 562 563 —CH3 564 565 566 —CH3 567 568 569 —CH3 570 571 572 —CH3 573 574 575 —CH3 576 577 578 —CH3 579 580 581 —CH3 582 583 584 —CH3 585 586 587 —CH3 588

### Claim 9 (depends on 1)

A pharmaceutical composition comprising an effective amount of a CCR5 antagonist of claim 1 in combination with a pharmaceutically acceptable carrier.

### Claim 10 (depends on 1)

A method of treating Human Immunodeficiency Virus comprising administering to a human in need of such treatment a therapeutically effective amount of a CCR5 antagonist of claim 1.

### Claim 11 (depends on 1, 10)

The method of claim 10 further comprising administering one or more antiviral or other agents useful in the treatment of Human Immunodeficiency Virus in combination with the CCR5 antagonist of claim 1.

### Claim 12 (depends on 11)

The method of claim 11 wherein the antiviral agent is selected from the group consisting of nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors.

### Claim 13 (depends on 12)

The method of claim 12 wherein the antiviral agent is selected from the group consisting of zidovudine, lamivudine, zalcitabine, didanosine, stavudine, abacavir, adefovir dipivoxil, lobucavir, BC H-10652, emitricitabine, beta-L-FD4, DAPD, lodenosine, nevirapine, delaviridine, efavirenz, PNU-142721, AG-1549, MKC-442, (+)-calanolide A and B, saquinavir, indinavir, ritonavir, nelfinavir, lasinavir, DMP-450, BMS-2322623, ABT-378, amprenavir, hydroxyurea, ribavirin, IL-2, IL-12, pentafuside, Yissum No. 1 1607 and AG-1549.

### Claim 14 (depends on 1)

A method treating solid organ transplant rejection, graft v. host disease, inflammatory bowel disease, rheumatoid arthritis or multiple sclerosis comprising administering to a human in need of such treatment a therapeutically effective amount of a CCR5 antagonist of claim 1.

### Claim 15

A method of treating Human Immunodeficiency Virus, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis, comprising administering to a human in need of such treatment a therapeutically effective amount of a CCR5 antagonist of the structural formula I:
589
or a pharmaceutically acceptable salt thereof, wherein
R is R8-phenyl, R8-pyridyl, R8-thiophenyl or R8-naphthyl;
R1 is hydrogen or C1-C6 alkyl;
R2 is R9, R10, R11-phenyl; R9, R10, R11-substituted 6-membered heteroaryl; R9, R10, R11-substituted 6-membered heteroaryl N-oxide; R12, R13-substituted 5-membered heteroaryl; naphthyl; fluorenyl; diphenylmethyl
590
R3 is hydrogen, C1-C6 alkyl, (C1-C6)alkoxy(C1-C6)alkyl, C3-C10 cycloalkyl, C3-C10 cycloalkyl(C1-C6)alkyl, R8-phenyl, R8-phenyl(C1-C6)alkyl, R8-naphthyl, R8-naphthyl(C1-C6)alkyl, R8-heteroaryl or R8-heteroaryl(C1-C6)alkyl;
R4, R5, R7 and R13 are independently selected from the group consisting of hydrogen and (C1-C6)-alkyl;
R6 is hydrogen, C1-C6 alkyl or C2-C6 alkenyl;
R8 is 1 to 3 substituents independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, —CF3, CF3O—, CH3C(O)—, —CN, CH3SO2—, CF3SO2—, R14-phenyl, R14-benzyl, CH3C(═NOCH3), CH3C(═NOCH2CH3),
591
—NH2, —NHCOCF3, —NHCONH(C1-C6 alkyl), —NHCO(C1-C6 alkyl), —NHSO2(C1-C6 alkyl), 5-membered heteroaryl and
592
wherein X is —O—, —NH— or —N(CH3)—;
R9 and R10 are independently selected from the group consisting of (C1-C6)alkyl, halogen, —NR17R18, —OH, —CF3, —OCH3, —O-acyl, —OCF3 and -Si(CH3)3;
R11 is R9, hydrogen, phenyl, —NO2, —CN, —CH2F, —CHF2, —CHO, —CH═NOR , pyridyl, pyridyl N-oxide, pyrimidinyl, pyrazinyl, —N(R17)CONR18R19, —NHCONH(chloro-(C1-C6)alkyl), —NHCONH((C3-C1)cycloalkyl(C1-C6)alkyl), —NHCO(C,-C6)alkyl, —NHCOCF3, —NHSO2N((C1-C6)alkyl)2, —NHSO2(C1-C6)alkyl, —N(SO2CF3)2, —NHCO2(C1-C6)alkyl, C3-C10 cycloalkyl, —SR20, —SOR20, —SO2R20, —SO2NH(C1-C6 alkyl), —OSO2(C1C6)alkyl, —OSO2CF3, hydroxy(C1-C6)alkyl, —CON R17R18, —CON(CH2CH2—O—CH3)2, —OCONH(C1-C6)alkyl, —CO2R17, —Si(CH3)3 or -B(OC(CH3)2)2;
R12 is (C1-C6)alkyl, —NH2 or R14-phenyl;
R14 is 1 to 3 substituents independently selected from the group consisting of hydrogen, (C1-C6) alkyl, —CF3, —CO2R17, —CN, (C1-C6)alkoxy and halogen;
R15 and R16 are independently selected from the group consisting of hydrogen and C1-C6 alkyl, or R15 and R16 together are a C2-C5 alkylene group and with the carbon to which they are attached form a spiro ring of 3 to 6 carbon atoms;
R17, R18 and R19 are independently selected from the group consisting of H and C1-C6 alkyl; and
R20 is C1-C6 alkyl or phenyl.

### Claim 16 (depends on 15)

The method of claim 15 wherein R is R8-phenyl or R8-naphthyl.

### Claim 17 (depends on 16)

The method of claim 16 wherein R is
593

### Claim 18 (depends on 15)

The method of claim 15 wherein R3 is hydrogen, (C1-C6) alkyl, R8-phenyl, R8-benzyl or R8-pyridyl.

### Claim 19 (depends on 15)

The method of claim 15 wherein R1 is hydrogen and R6 is hydrogen or methyl.

### Claim 20 (depends on 15)

The method of claim 15 wherein R2 is R9, R10, R11-phenyl; R9, R10, R11-pyridyl or an N-oxide thereof, or R9, R10, R11-pyrimidyl.

### Claim 21 (depends on 20)

The method of claim 20 wherein R2 is selected from the group consisting of
594
wherein R9 and R10 are selected from the group consisting of (C1-C6)alkyl, halogen, —OH and —NH2.

### Claim 22 (depends on 21)

The method of claim 21 wherein R2 is phenyl or pyridyl and R11 is hydrogen, or wherein R2 is pyrimidyl and R11 is hydrogen, methyl or phenyl.

### Claim 23 (depends on 15)

The method of claim 15 for the treatment of Human Immunodeficiency Virus, further comprising one or more antiviral or other agents useful in the treatment of Human Immunodeficiency Virus.

### Claim 24 (depends on 23)

The method of claim 23 wherein the antiviral agent is selected from the group consisting of nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors.

### Claim 25 (depends on 15)

The method of claim 15 for the treatment of solid organ transplant rejection, graft v. host disease, inflammatory bowel disease, rheumatoid arthritis or multiple sclerosis, further comprising one or more other agents useful in the treatment of said diseases.

### Claim 26 (depends on 15)

A kit comprising in separate containers in a single package pharmaceutical compositions for use in combination to treat Human Immunodeficiency Virus which comprises in one container a pharmaceutical composition comprising an effective amount of a CCR5 antagonist of claim 15 in a pharmaceutically acceptable carrier, and in separate containers, one or more pharmaceutical composition comprising an effective amount of a antiviral or other agent useful in the treatment of Human Immunodeficiency Virus in a pharmaceutically acceptable carrier.
